Needham reiterated coverage on NextCure with a new price target
$NXTC
Biotechnology: Pharmaceutical Preparations
Health Care
Needham reiterated coverage of NextCure with a rating of Buy and set a new price target of $14.00 from $30.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 3/1/2022 | $16.00 | Buy | Ladenburg Thalmann |
| 11/5/2021 | $30.00 → $14.00 | Buy | Needham |
Ladenburg Thalmann downgraded NextCure from Buy to Neutral
Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00
Needham reiterated coverage of NextCure with a rating of Buy and set a new price target of $14.00 from $30.00 previously
3 - NextCure, Inc. (0001661059) (Issuer)
4 - NextCure, Inc. (0001661059) (Issuer)
4 - NextCure, Inc. (0001661059) (Issuer)